119. Microdosing for Midlife: Brain Science of Change (Week 2)

Week 2 of Microdosing for Midlife explores estrogen, menopause, hormone therapy, and cognitive health—plus how psilocybin supports neuroplasticity.

Episode Summary

This episode marks Week 2 of Microdosing for Midlife, a 12-week audio series exploring how psilocybin microdosing for women intersects with hormonal change, emotional regulation, and cognitive resilience during midlife.

In this installment, April Pride expands on a central question that surfaced after Week 1: whether being “spared” classic menopausal symptoms—or choosing not to take hormone replacement therapy—puts women at greater risk for cognitive decline. Drawing from current research, April reframes the fear-driven narrative around menopause, estrogen, and dementia, offering a more nuanced and reassuring understanding of what actually shapes long-term brain health.

The episode also explores estrogen’s role as a neuroprotectant, how the midlife brain becomes more vulnerable to stress-based patterning, and why psychedelics like psilocybin may support neuroplasticity by softening rigid survival scripts. Through personal reflection and lived experience, April illustrates how subtle shifts in perception—not emotional erasure—can change one’s relationship to anxiety, grief, and uncertainty.

This episode functions as an audio companion to the written Week 2 essay, adding scientific context, integration insights, and real-life application without replacing the original post.

🔵 Key Takeaways

• Menopause as a neurological transition, not just a hormonal one• Estrogen’s role in cognition, mood, and neuroprotection• Why high symptom burden—not absence of symptoms—is linked to later cognitive risk• What hormone therapy does and does not do for long-term cognition• The default mode network and midlife rumination patterns• Psychedelics, neuroplasticity, and loosening fear-based survival scripts• Microdosing as a tool for integration rather than emotional suppression

🔵 Timestamps

[00:00] Reflections on Psychedelic Salon and Women in the Wild[02:30] Introducing Week 2 and the HRT cognition question[03:45] Menopausal symptoms and cognitive risk[05:00] What hormone therapy research actually shows[06:30] Estrogen as a neuroprotectant[08:30] Brain changes during midlife[10:00] Psychedelics and neuroplasticity[11:30] Personal reflections on anxiety and action[13:30] Reflection questions for listeners[15:00] Micro-Psyched program overview and what’s next

🔵 Additional Resources

Original Week 2 post on Substack

Episode 55: Ketamine-Assisted Therapy: Brain Effects Explained

Women in the Wild - Reserve your spot!

Learn more about this episode: https://aprilpride.substack.com/p/microdosing-for-midlife-estrogen-cognition

Hosted by April Pride

Subscribe for April’s newsletter on Substack at https://aprilpride.substack.com/subscribe or at getsetset.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Follow on IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset

Get full access to April Pride at aprilpride.substack.com/subscribe